Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Koji Goto; Takeshi Kimura; Ryuji Nohara; Hisao Ogawa; Akinori Takizawa; Minoru Horie; Mitsuhiko Yahata; Satoshi Shizuta; Manabu Shirotani; Yutaka Furukawa; Hiroki Shiomi; Satoru Suwa; Kazuaki Mitsudo; Katsuhisa Ishii; Kazushige Kadota; Yoshiki Takatsu; Yoshihisa Nakagawa; Takeshi Morimoto; Tsukasa Inada; Hiroshi Eizawa; Takeru Makiyama; Masahiro Natsuaki; Teruki Takeda; Shinji Miki; Masayuki Kato; Jong-Dae Lee; Masaaki Takahashi; Mamoru Takahashi; Kentaro Nakai; Takashi Tamura; Mitsuo Matsuda; Masakiyo Nobuyoshi; Toru Kita; Chihiro Ota; Shuichi Hamasaki; Takeshi Aoyama; Osamu Doi; Koh Ono

doi:10.1016/j.amjcard.2014.03.060

Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Koji Goto(Japan Science and Technology Agency), Takeshi Kimura(Kyoto University), Ryuji Nohara, Hisao Ogawa(Jikei University School of Medicine), Akinori Takizawa(Hyogo Medical University), Minoru Horie(Shiga University of Medical Science), Mitsuhiko Yahata(Kyoto University), Satoshi Shizuta(Kyoto University), Manabu Shirotani(Hyogo Medical University), Yutaka Furukawa(Kobe City Medical Center General Hospital), Hiroki Shiomi(Kyoto University), Satoru Suwa(Juntendo University Shizuoka Hospital), Kazuaki Mitsudo(Kurashiki Central Hospital), Katsuhisa Ishii(Hyogo Medical University), Kazushige Kadota(Kurashiki Central Hospital), Yoshiki Takatsu(Hyogo Medical University), Yoshihisa Nakagawa(Tenri Hospital), Takeshi Morimoto(Hyogo Medical University), Tsukasa Inada(Osaka Red Cross Hospital), Hiroshi Eizawa(Hyogo Medical University), Takeru Makiyama(Kyoto University), Masahiro Natsuaki(Saga University), Teruki Takeda(Hyogo Medical University), Shinji Miki(Hyogo Medical University), Masayuki Kato(Hyogo Medical University), Jong-Dae Lee(Hyogo Medical University), Masaaki Takahashi(Hamamatsu Rosai Hospital), Mamoru Takahashi(Hyogo Medical University), Kentaro Nakai(Kyoto University), Takashi Tamura(Japanese Red Cross Society Wakayama Medical Center), Mitsuo Matsuda(Hyogo Medical University), Masakiyo Nobuyoshi(Kurume University), Toru Kita(Hyogo Medical University), Chihiro Ota(Kyoto University), Shuichi Hamasaki(Hyogo Medical University), Takeshi Aoyama(Hyogo Medical University), Osamu Doi(Shizuoka General Hospital), Koh Ono(Kyoto University)

The American Journal of Cardiology

April 24, 2014

10.1016/j.amjcard.2014.03.060

Cited by 56

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

|New England Journal of Medicine|2017|9.1k

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

|The Lancet|2017|1.3k

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

|The Lancet|2017|881

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI

|JAMA|2019|830

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

|New England Journal of Medicine|2011|753